Orphanet Journal of Rare Diseases

Table 2 Utility values of patients treated with cerliponase alfa using the UK EQ-5D-5L value set

From: Investigating health-related quality of life in rare diseases: a case study in utility value determination for patients with CLN2 disease (neuronal ceroid lipofuscinosis type 2)

Disease stage	Cerliponase alfa
Disease stage	Mean value	Standard error	Median value	Minimum value	Maximum value
6	0.990	0.010	1.000	0.924	1.000
5	0.850	0.008	0.846	0.825	0.901
4	0.745	0.019	0.761	0.642	0.801
3	0.502	0.061	0.539	0.302	0.666
2	0.474	0.060	0.436	0.267	0.666
1	0.338	0.053	0.317	0.167	0.652
0	0.129	0.057	0.179	− 0.213	0.282
0 + VL	0.119	0.065	0.186	− 0.281	0.282
0 + VL + PC	0.104	0.065	0.174	− 0.281	0.268

Disease progression increases with decreasing disease stage. Utility values are given on a scale where 1 is equivalent to perfect health, and 0 equivalent to death. UK value set
PC, palliative care; VL, vision loss

Back to article page

ISSN: 1750-1172

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com